> top > docs > PubMed:26864319 > annotations

PubMed:26864319 JSONTXT

Annnotations TAB JSON ListView MergeView

DisGeNET5_gene_disease

Id Subject Object Predicate Lexical cue
26864319-2#101#115#gene183 353-367 gene183 denotes angiotensin II
26864319-2#9#22#diseaseC0018801 261-274 diseaseC0018801 denotes heart failure
26864319-2#9#22#diseaseC0018802 261-274 diseaseC0018802 denotes heart failure
26864319-9#42#52#gene4311 1592-1602 gene4311 denotes neprilysin
26864319-9#229#239#gene4311 1779-1789 gene4311 denotes neprilysin
26864319-9#187#189#diseaseC0018801 1737-1739 diseaseC0018801 denotes HF
26864319-9#187#189#diseaseC0018802 1737-1739 diseaseC0018802 denotes HF
26864319-9#187#189#diseaseC0018801 1737-1739 diseaseC0018801 denotes HF
26864319-9#187#189#diseaseC0018802 1737-1739 diseaseC0018802 denotes HF
101#115#gene1839#22#diseaseC0018801 26864319-2#101#115#gene183 26864319-2#9#22#diseaseC0018801 associated_with angiotensin II,heart failure
101#115#gene1839#22#diseaseC0018802 26864319-2#101#115#gene183 26864319-2#9#22#diseaseC0018802 associated_with angiotensin II,heart failure
42#52#gene4311187#189#diseaseC0018801 26864319-9#42#52#gene4311 26864319-9#187#189#diseaseC0018801 associated_with neprilysin,HF
42#52#gene4311187#189#diseaseC0018802 26864319-9#42#52#gene4311 26864319-9#187#189#diseaseC0018802 associated_with neprilysin,HF
42#52#gene4311187#189#diseaseC0018801 26864319-9#42#52#gene4311 26864319-9#187#189#diseaseC0018801 associated_with neprilysin,HF
42#52#gene4311187#189#diseaseC0018802 26864319-9#42#52#gene4311 26864319-9#187#189#diseaseC0018802 associated_with neprilysin,HF
229#239#gene4311187#189#diseaseC0018801 26864319-9#229#239#gene4311 26864319-9#187#189#diseaseC0018801 associated_with neprilysin,HF
229#239#gene4311187#189#diseaseC0018802 26864319-9#229#239#gene4311 26864319-9#187#189#diseaseC0018802 associated_with neprilysin,HF
229#239#gene4311187#189#diseaseC0018801 26864319-9#229#239#gene4311 26864319-9#187#189#diseaseC0018801 associated_with neprilysin,HF
229#239#gene4311187#189#diseaseC0018802 26864319-9#229#239#gene4311 26864319-9#187#189#diseaseC0018802 associated_with neprilysin,HF

DisGeNet-2017-sample

Id Subject Object Predicate Lexical cue
T410 353-367 gene:183 denotes angiotensin II
T411 261-274 disease:C0018801 denotes heart failure
T412 1592-1602 gene:4311 denotes neprilysin
T413 1737-1739 disease:C0018801 denotes HF
T414 1779-1789 gene:4311 denotes neprilysin
R1 T410 T411 associated_with angiotensin II,heart failure
R2 T410 T411 associated_with angiotensin II,heart failure
R3 T412 T413 associated_with neprilysin,HF
R4 T412 T413 associated_with neprilysin,HF
R5 T414 T413 associated_with neprilysin,HF
R6 T414 T413 associated_with neprilysin,HF

sentences

Id Subject Object Predicate Lexical cue
TextSentencer_T1 0-114 Sentence denotes Different Susceptibility of B-Type Natriuretic Peptide (BNP) and BNP Precursor (proBNP) to Cleavage by Neprilysin:
TextSentencer_T2 115-147 Sentence denotes The N-Terminal Part Does Matter.
TextSentencer_T3 148-159 Sentence denotes BACKGROUND:
TextSentencer_T4 160-251 Sentence denotes Protease neprilysin is known to be responsible for the degradation of natriuretic peptides.
TextSentencer_T5 252-537 Sentence denotes A recent heart failure (HF) drug, LCZ696 (Entresto(TM)), that combines a neprilysin inhibitor and an angiotensin II receptor inhibitor was suggested to augment circulating B-type natriuretic peptide (BNP) concentrations, making the results of BNP measurements diagnostically ambiguous.
TextSentencer_T6 538-721 Sentence denotes Because the main form of measured BNP in HF patients is represented by its uncleaved precursor, proBNP, it is important to know the susceptibility of proBNP to cleavage by neprilysin.
TextSentencer_T7 722-857 Sentence denotes METHODS: BNP 1-32 and nonglycosylated and glycosylated forms of proBNP 1-108 were incubated with neprilysin for different time periods.
TextSentencer_T8 858-1130 Sentence denotes BNP immunoreactivity was analyzed using 2 sandwich immunoassays: one utilizing monoclonal antibody (mAb) KY-BNP-II (epitope 14-21) as capture with mAb 50E1 (epitope 26-32) for detection and a single-epitope sandwich BNP (SES-BNP) immunoassay specific to the epitope 11-17.
TextSentencer_T9 1131-1200 Sentence denotes Mass-spectrometry was applied to determine the sites of BNP cleavage.
TextSentencer_T10 1201-1209 Sentence denotes RESULTS:
TextSentencer_T11 1210-1295 Sentence denotes In contrast to BNP, both forms of proBNP were resistant to degradation by neprilysin.
TextSentencer_T12 1296-1536 Sentence denotes The SES-BNP assay was much less susceptible to the BNP cleavage by neprilysin compared with the immunoassay utilizing antibodies specific to the region 14-21, comprising the site Arg17-Ile18, known as the site of BNP cleavage by neprilysin.
TextSentencer_T13 1537-1549 Sentence denotes CONCLUSIONS:
TextSentencer_T14 1550-1790 Sentence denotes These findings suggest that modulation of neprilysin activity by specific inhibitors may not greatly influence the circulating concentrations of immunoreactive BNP, mostly represented in HF by proBNP, which is not susceptible to neprilysin.
TextSentencer_T15 1791-1960 Sentence denotes The different susceptibility of the BNP regions to neprilysin-dependent degradation highlights the importance of the choice of epitopes for reliable BNP immunodetection.
T1 0-114 Sentence denotes Different Susceptibility of B-Type Natriuretic Peptide (BNP) and BNP Precursor (proBNP) to Cleavage by Neprilysin:
T2 115-147 Sentence denotes The N-Terminal Part Does Matter.
T3 148-159 Sentence denotes BACKGROUND:
T4 160-251 Sentence denotes Protease neprilysin is known to be responsible for the degradation of natriuretic peptides.
T5 252-537 Sentence denotes A recent heart failure (HF) drug, LCZ696 (Entresto(TM)), that combines a neprilysin inhibitor and an angiotensin II receptor inhibitor was suggested to augment circulating B-type natriuretic peptide (BNP) concentrations, making the results of BNP measurements diagnostically ambiguous.
T6 538-721 Sentence denotes Because the main form of measured BNP in HF patients is represented by its uncleaved precursor, proBNP, it is important to know the susceptibility of proBNP to cleavage by neprilysin.
T7 722-857 Sentence denotes METHODS: BNP 1-32 and nonglycosylated and glycosylated forms of proBNP 1-108 were incubated with neprilysin for different time periods.
T8 858-1130 Sentence denotes BNP immunoreactivity was analyzed using 2 sandwich immunoassays: one utilizing monoclonal antibody (mAb) KY-BNP-II (epitope 14-21) as capture with mAb 50E1 (epitope 26-32) for detection and a single-epitope sandwich BNP (SES-BNP) immunoassay specific to the epitope 11-17.
T9 1131-1200 Sentence denotes Mass-spectrometry was applied to determine the sites of BNP cleavage.
T10 1201-1209 Sentence denotes RESULTS:
T11 1210-1295 Sentence denotes In contrast to BNP, both forms of proBNP were resistant to degradation by neprilysin.
T12 1296-1536 Sentence denotes The SES-BNP assay was much less susceptible to the BNP cleavage by neprilysin compared with the immunoassay utilizing antibodies specific to the region 14-21, comprising the site Arg17-Ile18, known as the site of BNP cleavage by neprilysin.
T13 1537-1549 Sentence denotes CONCLUSIONS:
T14 1550-1790 Sentence denotes These findings suggest that modulation of neprilysin activity by specific inhibitors may not greatly influence the circulating concentrations of immunoreactive BNP, mostly represented in HF by proBNP, which is not susceptible to neprilysin.
T15 1791-1960 Sentence denotes The different susceptibility of the BNP regions to neprilysin-dependent degradation highlights the importance of the choice of epitopes for reliable BNP immunodetection.

UBERON-AE

Id Subject Object Predicate Lexical cue
PD-UBERON-AE-B_T1 261-266 http://purl.obolibrary.org/obo/UBERON_0000948 denotes heart

performance-test

Id Subject Object Predicate Lexical cue
PD-UBERON-AE-B_T1 261-266 http://purl.obolibrary.org/obo/UBERON_0000948 denotes heart